scientific brief, 2 March 2022
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
...(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen ...attribute-to-highlight medbox">COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
The World Health Organization (WHO) recognizes the challenges countries face for maintaining their COVID-19 response while addressing competing public health challenges, conflicts, climate change and economic crises. WHO continues to support countri...es in adjusting COVID-19 strategies to reflect successes to date and leverage what has been learned through national responses.
To assist national and global efforts to end the COVID-19 emergency worldwide, WHO updated the COVID-19 (Global Preparedness, Readiness and Response plan) in 2022 and outlined two strategic objectives.
more
This guide is available in English, French, Spanish, Russian, Arabic and Chinese
This guide consolidates COVID-19 guidance for human resources for health managers and policy-makers at national, subnational and facility levels to design, manage and ...preserve the workforce necessary to manage the COVID-19 pandemic and maintain essential health services.
The guide identifies recommendations to protect, support and empower health workers at individual, management, organizational and system levels.
more
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s...ummary included in the background document referenced below.
This document has been updated: Version 15 March 2022.
more
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
27 May 2021
All countries should increase their level of preparedness, alert and response to identify, manage and care for new cases of COVID-19. Countries should prepare to respond to different public health scenarios, recognizing that there is no... one-size-fits-all approach to managing cases and outbreaks of COVID-19. Each country should assess its risk and rapidly implement the necessary measures at the appropriate scale to reduce both COVID-19 transmission and economic, public and social impacts.
more
La capacidad de respuesta de un hospital puede ser superada por la llegada masiva de pacientes que soliciten atención médica como consecuencia de una situación de emergencia. Ante este escenario, se debe considerar si el establecimiento de salud está organizado para garantizar la gestión integr...al de la respuesta hospitalaria, el funcionamiento de los mecanismos de coordinación, el manejo integral de la información, las capacidades logísticas para facilitar la respuesta, y los recursos necesarios para su ejecución, así como para una respuesta integral a los pacientes, precautelando la salud y bienestar de los trabajadores de salud. (7)
more
Lignes directrices provisoires, 13 août 2020
L’OMS a établi cette brève note d’information pour répondre au besoin de recommandations sur la prestation sûre de soins à domicile aux patients présumés atteints de l’infection par le nouveau coronavirus (2019-nCoV) présentant des symptô...mes bénins, et sur les mesures de santé publique liées à la prise en charge des contacts asymptomatiques.
more
Orientação provisória, 6 de abril de 2020
Este documento resume as recomendações da OMS para o uso racional de equipamentos de proteção individual (EPIs) em unidades de saúde e na assistência domiciliar, bem como no manuseio de cargas; avalia também a situação atual da cadeia de abastec...imento global e as considerações para tomada de decisão durante desabastecimentos graves de EPIs.Este documento não inclui recomendações para membros da comunidade em geral. Clique aqui para mais informações sobre recomendações da OMS para uso de máscara na comunidade em geral.Nesse contexto, EPIs incluem luvas, máscaras faciais cirúrgicas/de uso médico - aqui denominadas “máscaras cirúrgicas”, óculos de proteção, protetor facial do tipo face shield, e aventais, bem como itens para procedimentos específicos - respiradores com máscara facial de filtração (padrão N95 ou PFF2 ou PFF3 ou equivalente) - aqui denominados “respiradores” - e capotes
more
This Interim Guidance is intended for field coordinators, site managers and public health personnel, as well as national and local governments and the wider humanitarian community working in humanitarian situations at food distribution sites, who are involved in the decision making and implementatio...n of multi-sectorial COVID-19 outbreak readiness and response activities – the Guidance is therefore relevant for all Humanitarian Clusters and their partners.
more
The 2014–2015 Ebola outbreak was catastrophic in West Africa but the indirect impact of increasing the mortality rates of other conditions was also substantial. The increased number of deaths caused by malaria, HIV/AIDS, and tuberculosis attributable to health system failures exceeded deaths from ...Ebola.
With a relatively limited COVID-19 caseload, health systems may have the capacity to maintain routine service delivery in addition to managing COVID-19 cases. When caseloads are high, and/or health workers are directly affected, strategic adaptations are required to ensure that increasingly limited resources provide maximum benefit for the refugees and surrounding host population. The following are key considerations for UNHCR operations on prioritized health care services in the event of a COVID-19 outbreak. These are based on WHO Guidance for Maintaining Essential Health Services and UNHCR guidance for operations and where relevant operation or site level outbreak preparedness and response plans.
more
This document provides guidance for African Union Member States on actions to be taken to ensure they continue to meet all the health
needs of their citizens in accordance with achieving the objectives of the Africa Health Strategy 2016 – 2030.
Updated 2022. This guide addresses the care pathway from presentation of the patient to a health facility to patient discharge. It considers different levels of disease severity, from asymptomatic individuals to critically ill patients. Accounting for variations in the benefits and harms of chest im...aging in different situations, remarks are provided to describe the circumstances under which each recommendation would benefit patients. The guide also includes implementation considerations for different settings, provides suggestions for impact monitoring and evaluation and identifies knowledge gaps meriting further research.
more